National, subnational and risk attributed burden of chronic respiratory diseases in Iran from 1990 to 2019.
Asthma
Attributable risk factor
COPD
Chronic respiratory disease
DALYs
Decomposition
Global burden of disease
Iran
Pneumoconiosis
Journal
Respiratory research
ISSN: 1465-993X
Titre abrégé: Respir Res
Pays: England
ID NLM: 101090633
Informations de publication
Date de publication:
11 Mar 2023
11 Mar 2023
Historique:
received:
20
08
2022
accepted:
28
01
2023
entrez:
11
3
2023
pubmed:
13
3
2023
medline:
15
3
2023
Statut:
epublish
Résumé
Data on the distribution of the burden of diseases is vital for policymakers for the appropriate allocation of resources. In this study, we report the geographical and time trends of chronic respiratory diseases (CRDs) in Iran from 1990 to 2019 based on the Global burden of the Disease (GBD) study 2019. Data were extracted from the GBD 2019 study to report the burden of CRDs through disability-adjusted life years (DALYs), mortality, incidence, prevalence, Years of Life lost (YLL), and Years Lost to Disability (YLD). Moreover, we reported the burden attributed to the risk factors with evidence of causation at national and subnational levels. We also performed a decomposition analysis to determine the roots of incidence changes. All data were measured as counts and age-standardized rates (ASR) divided by sex and age group. In 2019, the ASR of deaths, incidence, prevalence, and DALYs attributed to CRDs in Iran were 26.9 (23.2 to 29.1), 932.1 (799.7 to 1091.5), 5155.4 (4567.2 to 5859.6) and 587,911 (521,418 to 661,392) respectively. All burden measures were higher in males than females, but in older age groups, CRDs were more incident in females than males. While all crude numbers increased, all ASRs except for YLDs decreased over the studied period. Population growth was the main contributor to the changes in incidence at a national and subnational levels. The ASR of mortality in the province (Kerman) with the highest death rate (58.54 (29.42 to 68.73) was four times more than the province (Tehran) with the lowest death rate (14.52 (11.94 to 17.64)). The risk factors which imposed the most DALYs were smoking (216 (189.9 to 240.8)), ambient particulate matter pollution (117.9 (88.1 to 149.4)), and high body mass index (BMI) (57 (36.3 to 81.8)). Smoking was also the main risk factor in all provinces. Despite the overall decrease in ASR of burden measures, the crude counts are rising. Moreover, the ASIR of all CRDs except asthma is increasing. This suggests that the overall incidence of CRDs will continue to grow in the future, which calls for immediate action to reduce exposure to the known risk factors. Therefore, expanded national plans by policymakers are essential to prevent the economic and human burden of CRDs.
Identifiants
pubmed: 36906596
doi: 10.1186/s12931-023-02353-1
pii: 10.1186/s12931-023-02353-1
pmc: PMC10006557
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
74Informations de copyright
© 2023. The Author(s).
Références
Cancers (Basel). 2021 Jul 16;13(14):
pubmed: 34298794
Lancet Respir Med. 2020 Jun;8(6):585-596
pubmed: 32526187
Int J Environ Res Public Health. 2020 Aug 10;17(16):
pubmed: 32785128
Panminerva Med. 2018 Dec;60(4):192-199
pubmed: 29856178
Eur Respir J. 2023 Jan 12;61(1):
pubmed: 36028253
Respir Res. 2020 Feb 11;21(1):49
pubmed: 32046720
Lancet. 2020 Oct 17;396(10258):1160-1203
pubmed: 33069325
Arch Iran Med. 2020 Jun 01;23(6):369-377
pubmed: 32536173
Eur Respir J. 2019 Jul 18;54(1):
pubmed: 31248951
Clin Respir J. 2018 Jun;12(6):2075-2083
pubmed: 29405628
JAMA Oncol. 2019 Dec 1;5(12):1749-1768
pubmed: 31560378
Respir Med. 2002 Dec;96(12):963-75
pubmed: 12477209
Respirology. 2016 Jan;21(1):14-23
pubmed: 26494423
BMJ Open. 2020 Sep 9;10(9):e038874
pubmed: 32907907
J Thorac Dis. 2016 Jan;8(1):E31-40
pubmed: 26904251
Iran J Allergy Asthma Immunol. 2016 Apr;15(2):93-104
pubmed: 27090362
J Asthma Allergy. 2021 Oct 28;14:1277-1284
pubmed: 34737580
Arch Iran Med. 2020 May 01;23(5):353-355
pubmed: 32383620
Front Public Health. 2020 Dec 16;8:571062
pubmed: 33415092
Arch Public Health. 2020 May 25;78:45
pubmed: 32509302
Lancet. 2020 Oct 17;396(10258):1223-1249
pubmed: 33069327
Respir Res. 2018 May 2;19(1):79
pubmed: 29716592
Respir Res. 2006 Mar 29;7:52
pubmed: 16571126
Am J Respir Crit Care Med. 2015 Jul 1;192(1):11-6
pubmed: 25945507
BMJ. 2015 Jul 01;351:h3021
pubmed: 26136356
Int J Prev Med. 2020 Jul 03;11:78
pubmed: 33033587
J Aerosol Med Pulm Drug Deliv. 2020 Aug;33(4):171-177
pubmed: 32423274
N Engl J Med. 1999 Jun 17;340(24):1881-7
pubmed: 10369852
Lancet. 2022 Apr 23;399(10335):1625-1645
pubmed: 35397236
Respirology. 2003 Mar;8(1):7-16
pubmed: 12856736
BMC Pulm Med. 2022 Apr 20;22(1):149
pubmed: 35443660
Lancet. 2020 Oct 17;396(10258):1204-1222
pubmed: 33069326
J Allergy Clin Immunol Pract. 2021 Jul;9(7):2645-2655.e14
pubmed: 33684635
J Am Coll Cardiol. 2020 Dec 22;76(25):2982-3021
pubmed: 33309175